PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för xuezhikang. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

22 hits

Bibliografisk träff 2023-01-01

Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized Controlled Trial.

Xu J, Zhu L, Xie Y, Zhang M, Xiao Z, Su R, Wen T, Liu L.

Curr Vasc Pharmacol · clinical trial protocol; research support, non-u.s. gov't; research-article; journal article · DOI 10.2174/1570161121666230328110215

Bibliografisk träff 2022-10-19

Establishment of a lipid metabolism disorder model in ApoEb mutant zebrafish.

Hu YX, You HM, Zhu RF, Liang YL, Li FF, Qin YW, Zhao XX, Liang C, Jing Q.

Atherosclerosis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.atherosclerosis.2022.10.008

Bibliografisk träff 2022-09-17

The effect of Xuezhikang capsule on gene expression profile in brown adipose tissue of obese spontaneously hypertensive rats.

Zhang S, Jiang Y, Wang X, Zhang H, Gu P, Gong Z, Jiang W, Zhang Y, Zhu Y.

J Ethnopharmacol · journal article · DOI 10.1016/j.jep.2022.115700

Bibliografisk träff 2021-12-21

The clinical effect of Xuezhikang combined with ezetimibe in the treatment of coronary heart disease in lipid-lowering treatment and its influence on blood lipid level.

Guo L, Zhao S, Zhao W.

Panminerva Med · journal article · DOI 10.23736/s0031-0808.21.04624-3

Bibliografisk träff 2021-12-20

Effect of Xuezhikang Therapy on Expression of Pulmonary Hypertension Related miR-638 in Patients With Low HDL-C Levels.

Cao R, Sun T, Xu R, Zheng J, Wang H, Wang X, Bai Y, Ye P.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2021.764046

Bibliografisk träff 2021-11-11

Comparing the effectiveness of Chinese patent medicines containing red yeast rice on hyperlipidaemia: A network meta-analysis of randomized controlled trials.

Xu G, Lin M, Dai X, Hu J.

Endocrinol Diabetes Metab · research support, non-u.s. gov't; research-article; network meta-analysis; journal article · DOI 10.1002/edm2.314

Bibliografisk träff 2021-08-25

Effect of "Natural Polypill", Xuezhikang on Serum Cholesterol Metabolism Markers in Early Menopausal Women with Hypercholesterolemia.

Feng Y, Lu SL, Jin XG, Gao J, Chen WP, Wang YX, Xu H, Wang LY.

Chin J Integr Med · randomized controlled trial; journal article · DOI 10.1007/s11655-021-3499-y

Bibliografisk träff 2021-08-09

Comparison of the Reductions in LDL-C and Non-HDL-C Induced by the Red Yeast Rice Extract Xuezhikang Between Fasting and Non-fasting States in Patients With Coronary Heart Disease.

Zhu LY, Wen XY, Xiang QY, Guo LL, Xu J, Zhao SP, Liu L.

Front Cardiovasc Med · research-article; journal article · DOI 10.3389/fcvm.2021.674446

Bibliografisk träff 2021-03-01

[Effects and mechanisms of Xuezhikang on preventing contrast-induced acute kidney injury in diabetic rats].

Zhou L, Liu DW, Zhang FF, Liu SY, Wang F, Liu ZS, Zhao Q.

Zhonghua Yi Xue Za Zhi · journal article · DOI 10.3760/cma.j.cn112137-20210120-00184

Bibliografisk träff 2020-09-04

A 26-week toxicological study of Xuezhikang (XZK), red yeast rice extract, in Beagle dogs with a 4-week recovery period.

Li C, Su C, Wang Y, Gao Y, Wang H, Tian J, Fu F.

Regul Toxicol Pharmacol · journal article · DOI 10.1016/j.yrtph.2020.104781

Bibliografisk träff 2020-08-01

Effects of Xuezhitong in Patients with Hypertriglyceridemia: a Multicentre, Randomized, Double-Blind, Double Simulation, Positive Drug and Placebo Parallel Control Study.

Jia W, Li Y, Wan J, Cui X, Lu J, Liu J, Li D, Li L, Zou T, Ding J, Lin Q.

Cardiovasc Drugs Ther · research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s10557-020-06965-3

Bibliografisk träff 2020-05-17

Efficacy and safety of xuezhikang once per day versus two times per day in patients with mild to moderate hypercholesterolaemia (APEX study): a protocol for a multicentre, prospective randomised controlled, open-label, non-inferiority study.

Wu Z, Wu D, Jiang J, Chen A, Zheng DD, Li J, Dong Y, Chen Y.

BMJ Open · clinical trial protocol; research support, non-u.s. gov't; research-article; journal article · DOI 10.1136/bmjopen-2019-034585

Bibliografisk träff 2020-04-09

Toxicological evaluation of, red rice yeast extract, Xuezhikang: Acute, 26-week chronic and genotoxicity studies.

Gao Y, Chen X, Li C, Wang H, Tian J, Fu F.

Regul Toxicol Pharmacol · journal article · DOI 10.1016/j.yrtph.2020.104654

Bibliografisk träff 2019-04-04

Xuezhikang improves the outcomes of cardiopulmonary resuscitation in rats by suppressing the inflammation response through TLR4/NF-κB pathway.

Liang L, Shao W, Shu T, Zhang Y, Xu S, Guo L, Zhou Y, Huang H, Sun P.

Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2019.108817

Bibliografisk träff 2018-06-19

Isoflavones enhance pharmacokinetic exposure of active lovastatin acid via the upregulation of carboxylesterase in high-fat diet mice after oral administration of Xuezhikang capsules.

Feng D, Ge C, Tan ZY, Sun JG, Xie Y, Yao L, Yan CX, Aa JY, Wang GJ.

Acta Pharmacol Sin · research-article; journal article · DOI 10.1038/s41401-018-0039-1

Bibliografisk träff 2018-02-01

[Chinese expert consensus on the use of Xuezhikang (2017 revised edition)].

Committee of Cardio-Cerebro-Vascular Diseases of Gerontological Society of China, Working Group of Chinese Expert Consensus on the Use of Xuezhikang.

Zhonghua Nei Ke Za Zhi · consensus statement; journal article · DOI 10.3760/cma.j.issn.0578-1426.2018.02.003

Bibliografisk träff 2017-11-30

Xuezhikang, an extract from red yeast rice, attenuates vulnerable plaque progression by suppressing endoplasmic reticulum stress-mediated apoptosis and inflammation.

Shen L, Sun Z, Chu S, Cai Z, Nie P, Wu C, Yuan R, Hu L, He B.

PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0188841

Bibliografisk träff 2017-11-14

Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans.

Xu RX, Zhang Y, Guo YL, Ma CY, Yao YH, Li S, Li XL, Qing P, Gao Y, Wu NQ, Zhu CG, Liu G, Dong Q, Sun J, Li JJ.

Chronic Dis Transl Med · research-article; journal article · DOI 10.1016/j.cdtm.2017.09.004

Bibliografisk träff 2017-08-31

Xuezhikang reduced arterial stiffness in patients with essential hypertension: a preliminary study.

Zheng J, Xiao T, Ye P, Miao D, Wu H.

Braz J Med Biol Res · research-article; journal article · DOI 10.1590/1414-431x20176363

Bibliografisk träff 2017-01-24

Effects of Statins and Xuezhikang on the Expression of Secretory Phospholipase A2, Group IIA in Rat Vascular Smooth Muscle Cells.

Xie Q, Zhang D.

Int Heart J · journal article · DOI 10.1536/ihj.16-163

Bibliografisk träff 2016-11-01

Xuezhikang ameliorates contrast media-induced nephropathy in rats via suppression of oxidative stress, inflammatory responses and apoptosis.

Chu S, Hu L, Wang X, Sun S, Zhang T, Sun Z, Shen L, Jin S, He B.

Ren Fail · journal article · DOI 10.1080/0886022x.2016.1207052

Bibliografisk träff 2004-08-16

Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease.

Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, Li YL.

Circulation · clinical trial; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1161/01.cir.0000139985.81163.ce